PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.98%
R&D growth exceeding 1.5x Biotechnology median of 4.28%. Jim Chanos would check for wasteful spending.
58.15%
G&A growth exceeding 1.5x Biotechnology median of 0.89%. Jim Chanos would check for bloated overhead.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.40%
Operating expenses growth exceeding 1.5x Biotechnology median of 6.85%. Jim Chanos would check for waste.
20.40%
Total costs growth exceeding 1.5x Biotechnology median of 7.25%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
2.78%
D&A growth exceeding 1.5x Biotechnology median of 0.69%. Jim Chanos would check for overinvestment.
-20.82%
EBITDA decline while Biotechnology median is -5.66%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Operating income decline while Biotechnology median is -6.70%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
97.30%
Other expenses growth while Biotechnology reduces costs. Peter Lynch would examine differences.
-19.78%
Pre-tax income decline while Biotechnology median is -8.47%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.78%
Net income decline while Biotechnology median is -8.47%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
12.20%
EPS growth while Biotechnology declines. Peter Lynch would examine advantages.
12.20%
Diluted EPS change of 12.20% versus flat Biotechnology. Walter Schloss would verify quality.
35.62%
Share count reduction below 50% of Biotechnology median of 0.95%. Jim Chanos would check for issues.
35.62%
Diluted share reduction below 50% of Biotechnology median of 0.95%. Jim Chanos would check for issues.